Explore

Rapid Read Rapid Read
FDA Advisory Committee Recommends Lifting Regulations on Experimental Peptides Amidst Safety Concerns

FDA Advisory Committee Recommends Lifting Regulations on Experimental Peptides Amidst Safety Concerns

A U.S. drug advisory committee has recommended that the FDA lift regulations on several experimental peptides, allowing select pharmacies to manufacture and doctors to prescribe them. This decision comes despite the lack of large-scale human trials to support the safety and efficacy of these compounds. Peptides, which are short chains of amino acids, are being marketed for a variety of health benefits, including anti-aging and injury healing. The unregulated market for these peptides is estimated to be worth between $100 million and $3 billion. The committee's recommendation aims to mitigate risks associated with purchasing these products from unregulated sources, but it also raises concerns about the message it sends regarding their safety.
Rapid Read Rapid Read
FDA Announces Educational Webinar on Expedited IND Pilot Program

FDA Announces Educational Webinar on Expedited IND Pilot Program

The U.S. Food and Drug Administration (FDA) has announced an educational webinar scheduled for August 6, 2026, to discuss the proposed Expedited Investigational New Drug (IND) pilot program. This initiative aims to accelerate the transition from drug identification to first-in-human clinical trials. The program will establish a network of Qualified Research Institutions (QRIs), including academic medical centers, healthcare networks, and contract research organizations, to partner with sponsors in developing and reviewing protocols for IND submissions. The webinar will provide stakeholders with detailed information about the program's objectives and solicit feedback.
Trendline Trendline
Peptides Gain Popularity in Wellness Industry Amid Regulatory Concerns

Peptides Gain Popularity in Wellness Industry Amid Regulatory Concerns

Peptides Gain Popularity in Wellness Industry Amid Regulatory Concerns
Rapid Read Rapid Read
FDA Advisers Vote on Peptides for Drug Compounding List, Await Final Decision

FDA Advisers Vote on Peptides for Drug Compounding List, Await Final Decision

FDA advisers have narrowly voted to add six peptides to a drug compounding list, a decision that is non-binding and requires final approval from the FDA. This vote is part of ongoing efforts to regulate and expand the list of substances that can be legally compounded by pharmacies. The decision comes amid growing interest in the use of peptides for various therapeutic purposes, including their potential benefits in treating chronic conditions. The FDA's final decision will determine whether these peptides can be compounded, impacting pharmacies and patients seeking alternative treatment options.
Trendline Trendline
FDA's Stance on Single-Country Drug Trials Challenges Biopharma Companies

FDA's Stance on Single-Country Drug Trials Challenges Biopharma Companies

FDA's Stance on Single-Country Drug Trials Challenges Biopharma Companies
Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Rapid Read Rapid Read
Retatrutide Shows Promise in Weight Management, Awaits FDA Approval

Retatrutide Shows Promise in Weight Management, Awaits FDA Approval

Retatrutide, a drug not yet approved by the FDA, has shown significant promise in weight management during phase 2 trials, with participants losing an average of 24.2% of body weight over 48 weeks. This triple agonist drug activates three hormonal receptors, enhancing metabolic benefits. Despite its potential, access to retatrutide is currently limited to clinical trials and compounding pharmacies, with regulatory approval anticipated in the coming years.
Trendline Trendline
Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets
Trendline Trendline
Dasher Neuroscience Completes Enrollment for Phase 2 Trial of AI Drug for MSA

Dasher Neuroscience Completes Enrollment for Phase 2 Trial of AI Drug for MSA

Dasher Neuroscience Completes Enrollment for Phase 2 Trial of AI Drug for MSA
Trendline Trendline
Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment

Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment

Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment
Rapid Read Rapid Read
FDA Status and Safety Concerns Surround Semax Use in the U.S.

FDA Status and Safety Concerns Surround Semax Use in the U.S.

Semax, a synthetic peptide developed in Russia, is not FDA-approved for any medical indication in the United States. It is primarily sold as a research chemical, placing it in a regulatory gray area. The FDA has not evaluated Semax for safety or efficacy, and it cannot legally be marketed or sold as a drug or dietary supplement for human use. Most research supporting Semax comes from Russian-language literature, making independent verification challenging for Western researchers. Semax is believed to support focus and cognition through BDNF upregulation, but Western clinical evidence remains limited.
Trendline Trendline
FDA Recommits to Advisory Committees Amid Industry Concerns Over Expertise

FDA Recommits to Advisory Committees Amid Industry Concerns Over Expertise

FDA Recommits to Advisory Committees Amid Industry Concerns Over Expertise